Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23323211 | 1.00 | EPHX1 (0.43) | EPHX1L3MBTL1ALDH1A1MEN1POLB | |
| SCHEMBL20475792 | 0.88 | PRMT5 (0.36) | L3MBTL1 | |
| SCHEMBL22508975 | 0.88 | PRMT5 (0.36) | L3MBTL1 | |
| SCHEMBL20475791 | 0.88 | PRMT5 (0.36) | L3MBTL1 | |
| SCHEMBL20475669 | 0.83 | PRMT5 (0.38) | — | |
| SCHEMBL22508795 | 0.83 | PRMT5 (0.38) | — | |
| SCHEMBL20475671 | 0.83 | PRMT5 (0.38) | — | |
| SCHEMBL25593787 | 0.81 | EPHX1 (0.46) | EPHX1L3MBTL1ALDH1A1MEN1POLB | |
| SCHEMBL18026320 | 0.81 | PRMT5 (0.38) | — | |
| SCHEMBL24146558 | 0.80 | PRMT5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2023-06-08 | — | — | US | disclosed |
| US-11524962-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210403472-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403472-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | EPHX1 4266/4885L3MBTL1 1575/4885ALDH1A1 3752/4885 |
| US-11524962-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | EPHX1 3965/4885L3MBTL1 2469/4885ALDH1A1 3040/4885 |
| US-20230174539-A1 | Substituted Pyrrolo[2,3-D]Pyrimidines As Inhibitors Of Protein Arginine Methyl Transferase 5 (PRMT5) | PRMT5, PRMT1, PRMT3 | EPHX1 3978/4885L3MBTL1 2462/4885ALDH1A1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.